Avalyn Pharma Inc. (AVLN)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1540171 · fiscal year ends in Dec
Closing price $25.66 on 30 Oct 2026; 52-week range $23.33 to $39.25.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $1.1B
- Cash
- $264.2M
- Debt
- $14.8M
- Debt to equity
- 0.04
- Shares outstanding
- 44.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $2.7M | -$28.9M | -$0.98 |
| Q1 FY2026 | 31 Mar 2026 | $1.1M | -$26.9M | -$0.91 |
| Q2 FY2025 | 30 Jun 2025 | $1.6M | -$20.2M | -$17.63 |
| Q1 FY2025 | 31 Mar 2025 | $1.2M | -$17.5M | -$2.63 |
Company events
The newest 8-K filings of 6 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 16 Sep 2026 | 8-K | Leadership change | 5.02 |
| 12 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 1 Jul 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 17 Jun 2026 | 8-K | Investor update | 7.01 |
| 3 Jun 2026 | 8-K | Results | 2.02, 9.01 |
| 1 May 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
Every filing
The newest filings with the SEC of 24 held.
| Filed | Form | Period |
|---|---|---|
| 16 Sep 2026 | 8-K | 15 Sep 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 1 Jul 2026 | 8-K | 29 Jun 2026 |
| 17 Jun 2026 | 8-K | 17 Jun 2026 |
| 3 Jun 2026 | 10-Q | 31 Mar 2026 |
| 3 Jun 2026 | 8-K | 3 Jun 2026 |
| 1 May 2026 | 8-K | 1 May 2026 |
| 30 Apr 2026 | S-8 | – |
| 29 Apr 2026 | EFFECT | – |
| 29 Apr 2026 | CERT | – |
| 29 Apr 2026 | S-1/A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 May 2026 | Novo Holdings A/S, 10% owner | Purchase | 555,555 | $18.00 | $10.0M | 3,883,289 | 5 May 2026 |
| 1 May 2026 | Carroll Jill, Director | Purchase | 277,778 | $18.00 | $5.0M | 2,186,562 | 1 May 2026 |
| 1 May 2026 | Sr One Capital Management, Llc, 10% owner | Purchase | 277,778 | $18.00 | $5.0M | 2,186,562 | 1 May 2026 |
| 1 May 2026 | Sr One Capital Management, Llc, 10% owner | Purchase | 277,777 | $18.00 | $5.0M | 1,122,087 | 1 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Novo Holdings A/S | 13G | 8.8% | 3.9M |
| 11 Aug 2026 | Norwest Venture Partners XV, LP | 13G | 5.1% | 2.3M |
| 6 Aug 2026 | FMR LLC | 13G amended | 13.2% | 5.8M |
| 8 May 2026 | SR One Capital Management, LLC | 13D | 7.5% | 3.3M |
| 8 May 2026 | SUVRETTA CAPITAL MANAGEMENT, LLC | 13D | 5.6% | 2.5M |
| 7 May 2026 | Perceptive Advisors LLC | 13G | 6% | 2.7M |
| 5 May 2026 | FMR LLC | 13G | 11.5% | 4.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.4M | -6.44% | 6.63 |
| 30 Sep 2026 | 2.5M | +20.21% | 8.52 |
| 15 Sep 2026 | 2.1M | +8.44% | 9.56 |
| 31 Aug 2026 | 1.9M | -6.87% | 11.34 |
| 14 Aug 2026 | 2.1M | +2.65% | 10.93 |
| 31 Jul 2026 | 2.0M | -7.82% | 9.36 |
| 15 Jul 2026 | 2.2M | +1.14% | 5.62 |
| 30 Jun 2026 | 2.2M | +65.42% | 3.07 |
Funds that hold it
From each fund's latest Form 13F.
93 funds held it at 30 Jun 2026: 92 added and 0 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 5,835,259 | $192.1M | +5,835,259 |
| Novo Holdings A/s | 3,883,289 | $127.8M | +3,883,289 |
| SR One Capital Management, LP | 3,308,649 | $108.9M | +3,308,649 |
| Perceptive Advisors LLC | 2,675,296 | $88.1M | +2,675,296 |
| Montanova Capital, LLC | 2,503,109 | $82.4M | +2,503,109 |
| NVP Associates, LLC | 2,268,404 | $74.7M | +2,268,404 |
| Wellington Management Group LLP | 2,201,986 | $72.5M | +2,201,986 |
| Price T Rowe Associates Inc. | 1,735,231 | $57.1M | +1,735,231 |
| Catalio Capital Management, LP | 1,675,830 | $55.2M | +1,675,830 |
| T. Rowe Price Investment Management, Inc. | 1,602,745 | $52.8M | +1,602,745 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.33T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $657.6B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $521.0B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $368.9B
- Novartis AG (NVS): revenue $54.5B, market value $306.8B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $289.5B
- Abbott Laboratories (ABT): revenue $46.6B, market value $183.8B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $178.6B
- Pfizer Inc. (PFE): revenue $63.7B, market value $173.8B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $141.6B